Mostrar el registro sencillo del ítem

dc.contributor.author
Pandi Perumal, Seithikurippu R.  
dc.contributor.author
BaHammam, Ahmed S.  
dc.contributor.author
Brown, Gregory M.  
dc.contributor.author
Spence, David Warren  
dc.contributor.author
Bharti, Vijay K.  
dc.contributor.author
Kaur, Charanjit  
dc.contributor.author
Hardeland, Rüdiger  
dc.contributor.author
Cardinali, Daniel Pedro  
dc.date.available
2016-01-27T20:02:42Z  
dc.date.issued
2013-04  
dc.identifier.citation
Pandi Perumal, Seithikurippu R.; BaHammam, Ahmed S.; Brown, Gregory M.; Spence, David Warren; Bharti, Vijay K.; et al.; Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes; Springer; Neurotoxicity Research; 23; 3; 4-2013; 267-300  
dc.identifier.issn
1029-8428  
dc.identifier.uri
http://hdl.handle.net/11336/3859  
dc.description.abstract
The pineal product melatonin has remarkable antioxidant properties. It is secreted during darkness and plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation, and vasomotor responses. It scavenges hydroxyl, carbonate, and various organic radicals as well as a number of reactive nitrogen species. Melatonin also enhances the antioxidant potential of the cell by stimulating the synthesis of antioxidant enzymes including superoxide dismutase, glutathione peroxidase, and glutathione reductase, and by augmenting glutathione levels. Melatonin preserves mitochondrial homeostasis, reduces free radical generation and protects mitochondrial ATP synthesis by stimulating Complexes I and IV activities. The decline in melatonin production in aged individuals has been suggested as one of the primary contributing factors for the development of age-associated neurodegenerative diseases. The efficacy of melatonin in preventing oxidative damage in either cultured neuronal cells or in the brains of animals treated with various neurotoxic agents, suggests that melatonin has a potential therapeutic value as a neuroprotective drug in treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), stroke, and brain trauma. Therapeutic trials with melatonin indicate that it has a potential therapeutic value as a neuroprotective drug in treatment of AD, ALS, and HD. In the case of other neurological conditions, like PD, the evidence is less compelling. Melatonin’s efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke. Clinical trials employing melatonin doses in the range of 50–100 mg/day are warranted before its relative merits as a neuroprotective agent is definitively established.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Melatonin  
dc.subject
Mitochondria  
dc.subject
Free Radicals  
dc.subject
Oxidative Stress  
dc.subject
Aging  
dc.subject
Parkinson´S Disease  
dc.subject
Alzheimer´S Disease  
dc.subject
Huntington´S Disease  
dc.subject
Amyotrophic Lateral Sclerosis  
dc.subject
Stroke  
dc.subject.classification
Neurociencias  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.subject.classification
Neurología Clínica  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2016-03-30 10:35:44.97925-03  
dc.journal.volume
23  
dc.journal.number
3  
dc.journal.pagination
267-300  
dc.journal.pais
Alemania  
dc.journal.ciudad
Berlin  
dc.description.fil
Fil: Pandi Perumal, Seithikurippu R.. Somnogen Canada Inc.; Canadá. King Saud University. College of Medicine. Sleep Disorders Center; Arabia Saudita  
dc.description.fil
Fil: BaHammam, Ahmed S.. King Saud University. College of Medicine. Sleep Disorders Center; Arabia Saudita  
dc.description.fil
Fil: Brown, Gregory M.. University of Toronto. Department of Psychiatry; Canadá. Centre for Addiction and Mental Health; Canadá  
dc.description.fil
Fil: Spence, David Warren. No especifíca;  
dc.description.fil
Fil: Bharti, Vijay K.. Ministry of Defence. Defence Research and Development Organization. Defence Institute of High Altitude Research. Nutrition and Toxicology Laboratory; India  
dc.description.fil
Fil: Kaur, Charanjit. National University of Singapore. Yong Loo Lin School of Medicine. Department of Anatomy; Singapur  
dc.description.fil
Fil: Hardeland, Rüdiger. Universitat Gottingen. Institut fur Zoologie und Anthropologie; Alemania  
dc.description.fil
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Neurotoxicity Research  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://link.springer.com/article/10.1007%2Fs12640-012-9337-4  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s12640-012-9337-4  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/issn/1029-8428